Life science company Enzymatica has signed a partnership agreement with Stada for the launch and distribution of Coldzyme in Germany and Austria.

The product will be marketed as an oral spray under Stada's own proprietary brands.

The launch is being prepared for 2026 with initial deliveries, while a more significant commercial impact is expected starting from the 2026/2027 flu season.

The collaboration builds on the companies' existing relationship. No financial details were disclosed.

"This is a significant breakthrough for Enzymatica. Germany is the largest and most important market for cold and flu treatments in Europe. Entering into a partnership with Stada confirms Coldzyme's competitiveness and commercial relevance. With the right partner in place, we can build a long-term business and create the conditions for substantial sales volumes over time," says Sana Alajmovic, CEO of Enzymatica, in a statement.